Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr
The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che
GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer
Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe
The combination of Merck & Co’s PD-1 inhibitor Keytruda with experimental TIGIT inhibitor vibostolimab has generated disappointing results in a mid-stage lung cancer t